Vanda Pharmaceuticals
Clinical trials sponsored by Vanda Pharmaceuticals, explained in plain language.
Develops and commercializes therapies for central nervous system disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Promising psoriasis drug trial halted early – what now?
Disease control TerminatedThis study tested a drug called imsidolimab for adults with generalized pustular psoriasis (GPP), a rare and painful skin condition. The trial aimed to see if the drug is safe and works over the long term. However, the study was terminated early, so we have less information than …
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising ichthyosis drug trial stalls after just 5 patients
Disease control TerminatedThis study tested a drug called imsidolimab (ANB019) in people with ichthyosis, a condition that causes dry, scaly, and red skin. The trial aimed to see if the drug could improve skin symptoms compared to a placebo. However, the study was stopped early and only enrolled 5 partici…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 17:50 UTC
-
Cancer rash drug trial halted early – little known
Symptom relief TerminatedThis small, early-stage trial tested a drug called imsidolimab for treating acne-like skin rashes that can occur in cancer patients taking certain targeted therapies. Only 4 people were enrolled before the study was stopped. Because of the very small size and early termination, w…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC